{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"30.7","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Overall survival was determined from the on-study date until date of progression or last follow up. The probability of OS as a function of time was estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who received 3.4 mg/kg, 4.8 mg/kg, 8.5 mg/kg and 15 mg/kg siplizumab given on day 1 of each cycle followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Data collected from participants receiving different dose levels were combined and analyzed as a single Arm/Group as pre-specified in the study protocol.","reportingStatus":"POSTED","timeFrame":"On study date until date of death or last follow up, approximately 12 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}